Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q2 2019 Earnings Presentation

15 slides from Reata Pharmaceuticals's earnings presentation, Aug 8, 2019

  1. Slide 1: Second quarter 2019 earnings call

    Second quarter 2019 earnings call August 8, 2019 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement

  3. Slide 3: Reata at a Glance

    Strong financial position Cash of $280M, lasting through 3 pivotal readouts Franchise building Expansion into other rare forms of CKD2 and neurological diseases Addressing unmet needs Deadly rare diseases No approved therapy Little to no competition Two pivotal trials fully enrolled and reading out

  4. Slide 4: Bard Development for Rare Forms of CKD

    US Rare CKD Patients ADPKD T1D CKD FSGS IgAN Alport Syndrome ~400,000 ~160,000 ~120,000 ~40,000 ~30,000-60,000 Significant opportunity for Bard1 in rare forms of CKD Few or no effective therapies currently approved Aggregate prevalence exceeds 700,000 patients CARDINAL Phase 3 study in Alport syndro

  5. Slide 5: CARDINAL: Data in Alport Syndrome Expected this Year

    CARDINAL: Data in Alport Syndrome Expected this Year Pivotal Phase 3 enrolled 157 patients Randomized, double-blind, placebo-controlled international study Two-year total treatment duration Enrolled patients across approximately 50 sites in the U.S., Europe, Australia, and Japan Broad eligibility cr

  6. Slide 6: CARDINAL Phase 3 Analysis Plans

    CARDINAL Phase 3 Analysis Plans Adjusted the statistical analysis plan based on recent FDA review of tolvaptan Phase 3 study, REPRISE REPRISE used ANCOVA1 analysis method to support approval in ADPKD ANCOVA allows inclusion of patients who discontinued early, minimizing missing data Accordingly, CAR

  7. Slide 7: Phase 3 Trial of Bard for the Treatment of ADPKD: FALCON

    Pivotal Phase 3 is enrolling approximately 300 patients Randomized, double-blind, placebo-controlled international study Two-year total treatment duration Broad eligibility criteria eGFR 30-90 mL/min Age 18-70 years old Retained eGFR after drug withdrawal can support approval Potential accelerated a

  8. Slide 8: Bard CKD Program: Summary and Next Steps

    NDA1 preparations are underway Large safety database with over 2,000 people having been exposed to Bard Reata has conducted all pivotal preclinical toxicology studies and clinical pharmacology studies required for NDA submission for Alport syndrome Commercial preparations are underway Supply chain r

  9. Slide 9: MOXIe: Data in Friedreich's Ataxia Expected this Year

    MOXIe: Data in Friedreich’s Ataxia Expected this Year Pivotal portion enrolled 103 patients Randomized, double-blind, placebo-controlled international study of Omav1 in FA2 48-week total treatment duration Enrolled patients across 11 sites in the U.S., Europe, and Australia Broad eligibility criteri

  10. Slide 10: MOXIe Part 2 primary analysis population and pes cavus

    Pes cavus foot deformity likely interferes with the ability to perform assessments that require standing, walking or pedaling FDA recently published draft guidance “Enhancing Diversity of Clinical Trial Populations1” Encourages sponsors to study broader participant groups as part of secondary analys

  11. Slide 11: Omav FA Program: Summary and Next Steps

    Omav FA Program: Summary and Next Steps NDA preparations are underway FDA has provided written guidance that mFARS is an acceptable endpoint for approval for Omav in FA No major safety signals detected in completed trials Few remaining clinical pharmacology studies required for NDA submission are un

  12. Slide 12: Phase 3 Trial of Bard for Treatment of CTD-PAH: CATALYST

    Phase 3 Trial of Bard for Treatment of CTD-PAH: CATALYST Phase 3 enrolling 200 patients Randomized, double-blind, placebo-controlled international study of Bard in CTD-PAH1 24-week treatment duration Enrolling patients across approximately 100 sites in North America, Europe, Australia, South America

  13. Slide 13: Financial Highlights

    Condensed Statements of Operations Three Months Ended June 30 Six Months Ended June 30 (unaudited; in thousands, except share and per share data) 2019 2018 2019 2018 Total Revenue $7,833 $7,571 $15,603 $39,962 Expenses Research and development $29,554 $23,429 $55,668 $44,835 General and administrati

  14. Slide 14: Recent Highlights and Key Upcoming Milestones

    Bard in Alport syndrome Pivotal Phase 3 fully enrolled with data available in 2H19 Bard in ADPKD Pivotal Phase 3 trial in ADPKD initiated in May 2019 Omav in Friedreich’s ataxia Pivotal Phase 2, part 2 fully enrolled with data available in 2H19 Bard in CTD-PAH Phase 3 CATALYST pivotal data available

  15. Slide 15: Q&A

    Q&A

Reata Pharmaceuticals — Q2 2019 Earnings Presentation on 6ix